IRSF recognizes that some of the most transformative ideas originate from scientists at a pivotal moment in their careers—when they transition from postdoctoral fellows (postdocs) to independent principal investigators (PIs). This is an exciting but fragile stage, when bold new directions are often defined by whether early support is available.
This transition is the culmination of more than a decade of scientific training. Researchers typically spend around six years earning their Ph.D., but for those aspiring to lead their own research labs—a necessity to drive long-term innovation in fields like Rett syndrome—there is a critical next step: the postdoctoral fellowship.
During this period, scientists join established labs, develop independent research ideas, publish extensively, and gain essential skills such as mentorship and grant writing. Yet the journey to becoming a PI depends heavily on funding. To be hired as an assistant professor and to sustain their labs once established, researchers must secure competitive grants. Large grants require preliminary data, but generating that data itself requires funding. This catch-22 creates a major barrier for early-stage investigators and is precisely where IRSF plays an essential role.
One of the researchers IRSF has proudly supported at this critical juncture with an Independence Award Grant is Dr. Sameer Bajikar, whose work may open new therapeutic pathways for families living with Rett syndrome. His journey into the Rett field is connected to renowned neuroscientist Dr. Huda Zoghbi, whose discovery of the genetic cause of Rett syndrome fundamentally reshaped scientific understanding of the disorder.
A Scientific Lineage Built on a Landmark Discovery
In 1999, Dr. Huda Zoghbi and her research team at Baylor College of Medicine made the groundbreaking discovery that mutations in the MECP2 gene are the cause of Rett syndrome. This pivotal work linked Rett to a specific genetic mutation and revealed that loss or malfunction of the MeCP2 protein, an essential regulator of other genes, leads to the neurological symptoms seen in the disorder.
Seventeen years later, after earning his PhD in Biomedical Engineering at the University of Virginia, Dr. Bajikar shifted his focus from cancer biology to neurodevelopmental disorders, seeking a field rich with unanswered questions and ripe for basic science discovery. That journey led him, unexpectedly, to the laboratory of Rett pioneer Dr. Zoghbi.
“I did my postdoctoral fellowship in Huda Zoghbi’s lab totally by accident. I didn’t know who she was before I emailed her, but I was very grateful to work in her lab and learn from all her great accomplishments and her mentorship.”
In this environment, he gained deep insight into Rett biology while also shaping the independent research questions he would later pursue as a PI. His trajectory reflects the vital role of postdoctoral experiences in generating the next generation of scientific leaders.
Charting a New Therapeutic Direction
Now leading his own lab back at the University of Virginia, Dr. Bajikar focuses on the Mecp2 pathway. Directly targeting Mecp2 is challenging, so his strategy is to examine the molecules Mecp2 acts upon—targets that may be safer and easier to manipulate.
“I’m really interested in understanding the downstream targets of Mecp2, because targeting Mecp2 therapeutically can be difficult since you need to get it within a very tight window. However, if we can understand the targets that are downstream…they may be either easier to drug or may have a bigger safety window.”
One of those downstream targets is GDF11, a naturally occurring growth factor shown by his team to be reduced in Rett syndrome cells.
“So my favorite [downstream target] is a gene called GDF11 or Growth Differentiation Factor 11… I found that it’s decreased in Rett syndrome cells. So one avenue that we’re actively pursuing is trying to see what happens if we supplement that growth factor back and if we can improve any behavioral or disease aspects in Rett syndrome.”
This promising exploration highlights the critical importance of basic science research as the foundation for therapeutic innovation. Understanding unknown mechanisms and cellular pathways is the bedrock upon which drug discovery and translational research are built.
How IRSF Support Ignited a New Lab
For early investigators like Dr. Bajikar, generating the preliminary data needed to win major federal grants is impossible without seed funding. IRSF steps in at this formative stage with grant funding, enabling scientists to stay in the Rett field and pursue bold ideas that may otherwise remain unexplored.
“IRSF’s support has been extremely instrumental towards the start of my lab. I had the Independence Award, which funded the very tail end of my postdoc work and now the first two years of my lab. This is a pretty unique funding opportunity that let me really develop my own ideas.”
He continues:
“And now I have the continued support to really build those ideas, to be more fleshed out and competitive for more federal and long-standing funding. So that IRSF funding filled a really important gap for me to start to develop my ideas that really isn’t afforded to junior investigators.”
This “gap” is one that every early-career scientist faces: to get grants, you need preliminary data, but to get preliminary data, you need funding. IRSF breaks this cycle, enabling promising researchers to generate discoveries that attract additional investment from biotech, pharma, and federal agencies.
Looking Ahead: Momentum, Collaboration, and a Critical Moment for Investment
With his lab now established, Dr. Bajikar sees tremendous energy in the Rett research landscape.
“I think I see a lot of momentum in the research. I see a lot of the basic scientists and researchers coming to similar conclusions, which means now we’re really reproducing each other’s findings and coming to real, solid biology that we can now build off for the future. I’m seeing a lot of collaborations amongst individuals. So I think the momentum is definitely there. Pushing the research forward.”
He also believes the field stands on the verge of meaningful breakthroughs, and that investment now matters more than ever.
“This is an extremely critical time to invest in research. We have a lot of great observations that we can make a big impact for this disease, and we’re just right at the surface of making important breakthroughs. So I think this is the most critical time to really push forward at as fast and as big of a step as we can.”
To families and donors, he emphasizes how far their support goes:
“The impact is huge, especially for basic researchers. So it enables research that would otherwise not be able to happen. So every dollar that I get from IRSF directly goes to buying stuff that we need to do the experiments to make that critical data. So there isn’t a dollar wasted for that. And every dollar goes very far, especially in research.“
– Dr. Sameer Bajikar
A Continuum of Discovery
Rett research has advanced significantly since Dr. Huda Zoghbi’s discovery of the MECP2 gene, a breakthrough that transformed understanding of the disorder and set the stage for today’s scientific progress. Dr. Bajikar’s work continues that trajectory, adding new insight into molecular pathways and pointing toward emerging therapeutic possibilities.
The future of Rett research depends on ensuring that talented scientists can enter, and stay in, the field. By investing in early-career researchers and providing the seed funding needed to spark discovery, IRSF helps ensure that the next generation of breakthroughs can take root.
Each new idea builds on the decades of foundational science that came before it, strengthening hope for the cures and treatments still ahead.
You can make a direct impact by supporting critical Rett syndrome research and the researchers at the forefront of the next breakthroughs. Donate to our Research to Reality Fund to help drive progress to advance treatments and give hope to every individual with Rett syndrome.